Lars Fruergaard Jørgensen CEO of Novo Nordisk
In Good Company with Nicolai Tangen
Revolutionizing Obesity Treatment Through Innovative Drug Development
This chapter explores an innovative diabetes treatment that also significantly aids in obesity management through the GLP-1 mechanism. It discusses the benefits of appetite suppression and weight loss, while addressing the challenges in developing effective obesity medications.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
